Anti-myeloperoxidase and proteinase 3 antibodies for nephritis flare prediction in anti-neutrophil cytoplasmic antibody-associated vasculitis.

BACKGROUND: The value of myeloperoxidase (MPO) and proteinase 3 (PR3) antibody titres in the assessment of renal disease activity and flare prediction in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is not well known. METHODS: We performed a retrospective study including 113 AVV patients with renal biopsy-proven pauci-immune necrotizing glomerulonephritis from seven Spanish hospitals. The main inclusion criteria were assessment of MPO antibodies using multiplex flow immunoassay and PR3 antibody measurements using immunoassay chemiluminescence with an identical range of values for all participating centres. RESULTS: Serum MPO antibodies 3 ± 1.2 months before relapse were higher in patients who relapsed [19.2 ± 12.2 versus 3.2 ± 5.1 antibody index (AI); P < 0.001]. The discrimination value of MPO antibodies 3 months before renal relapse had an area under the receiver operating characteristics curve (AUC) of 0.82 [95% confidence interval (CI) 0.73-0.92; P < 0.001]. ΔMPO antibodies (change in antibodies titration 6 months before relapse) were higher in patients who relapsed (8.3 ± 12 versus 0.9 ± 3.1 AI; P = 0.001). The discrimination value of ΔMPO had an AUC of 0.76 (95% CI 0.63-0.88; P < 0.001). The positive predictive value of renal relapse in PR3 patients is 100% and the negative predictive value of renal relapse in patients with PR3-positive titres is 57.1%. Serum PR3 antibodies were higher in patients who relapsed 2.8 ± 1.4 months before relapse (58.6 ± 24.6 versus 2.0 ± 0.6 AI; P < 0.001). CONCLUSIONS: MPO level monitoring using multiplex flow immunoassay and PR3 measurements using immunoassay chemiluminescence are useful and sensitive tools for the prediction of renal relapse in the follow-up of AAV patients with renal disease and relevant surrogate markers of renal disease activity.

Complement Activation and Thrombotic Microangiopathies.

BACKGROUND AND OBJECTIVES: Atypical hemolytic uremic syndrome is a form of thrombotic microangiopathy caused by dysregulation of the alternative complement pathway. There is evidence showing complement activation in other thrombotic microangiopathies. The aim of this study was to evaluate complement activation in different thrombotic microangiopathies and to monitor treatment response. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Complement activation was assessed by exposing endothelial cells to sera or activated-patient plasma-citrated plasma mixed with a control sera pool (1:1)-to analyze C5b-9 deposits by immunofluorescence. Patients with atypical hemolytic uremic syndrome (n=34) at different stages of the disease, HELLP syndrome (a pregnancy complication characterized by hemolysis, elevated liver enzymes, and low platelet count) or severe preeclampsia (n=10), and malignant hypertension (n=5) were included. RESULTS: Acute phase atypical hemolytic uremic syndrome-activated plasma induced an increased C5b-9 deposition on endothelial cells. Standard and lower doses of eculizumab inhibited C5b-9 deposition in all patients with atypical hemolytic uremic syndrome, except in two who showed partial remission and clinical relapse. Significant fibrin formation was observed together with C5b-9 deposition. Results obtained using activated-plasma samples were more marked and reproducible than those obtained with sera. C5b-9 deposition was also increased with samples from patients with HELLP (all cases) and preeclampsia (90%) at disease onset. This increase was sustained in those with HELLP after 40 days, and levels normalized in patients with both HELLP and preeclampsia after 6-9 months. Complement activation in those with malignant hypertension was at control levels. CONCLUSIONS: The proposed methodology identifies complement overactivation in patients with atypical hemolytic uremic syndrome at acute phase and in other diseases such as HELLP syndrome and preeclampsia. Moreover, it is sensitive enough to individually assess the efficiency of the C5 inhibition treatment.

Escalas semánticas para la evaluación del ruido tercera etapa: caracterización subjetiva de estímulos sonoros / Semantic scales for noise evaluation third part: subjective characterization of sound stimuli

Tercera y última etapa de una investigación (5, 6) cuya finalidad fue la construcción de escalas adecuadas para la evaluación subjetiva de estímulos sonoros, utilizando la Técnica del diferencial semántico. El objetivo de esta etapa fue caracterizar 40 estímulos sonoros a través de un grupo de las escalas antes mencionadas y teniendo en cuenta las dimensiones psicológicas subyacentes obtenidas por el análisis factorial de las mismas. Para ello se aplicó un programa especial de diferencial semántico obteniéndose los siguientes índices: puntaje escalar, polaridad, familiaridad y distancia inter-conceptos. Se determinaron los estímulos sonoros mejor caracterizados y las escalas más adecuadas para evaluar cada concepto

Escalas semánticas para la evaluación del ruido tercera etapa: caracterización subjetiva de estímulos sonoros / Semantic scales for noise evaluation third part: subjective characterization of sound stimuli

Tercera y última etapa de una investigación (5, 6) cuya finalidad fue la construcción de escalas adecuadas para la evaluación subjetiva de estímulos sonoros, utilizando la Técnica del diferencial semántico. El objetivo de esta etapa fue caracterizar 40 estímulos sonoros a través de un grupo de las escalas antes mencionadas y teniendo en cuenta las dimensiones psicológicas subyacentes obtenidas por el análisis factorial de las mismas. Para ello se aplicó un programa especial de diferencial semántico obteniéndose los siguientes índices: puntaje escalar, polaridad, familiaridad y distancia inter-conceptos. Se determinaron los estímulos sonoros mejor caracterizados y las escalas más adecuadas para evaluar cada concepto (AU)